Investigation into the Effectiveness of an Herbal Combination (Angocin^®Anti-Infekt N) in the Therapy of Acute Bronchitis: A Retrospective Real-World Cohort Study.

IF 4.3 2区医学 Q1 INFECTIOUS DISEASES

Antibiotics-Basel Pub Date : 2024-10-17 DOI:10.3390/antibiotics13100982

Nina Kassner, Meinolf Wonnemann, Yvonne Ziegler, Rainer Stange, Karel Kostev

{"title":"Investigation into the Effectiveness of an Herbal Combination (Angocin®Anti-Infekt N) in the Therapy of Acute Bronchitis: A Retrospective Real-World Cohort Study.","authors":"Nina Kassner, Meinolf Wonnemann, Yvonne Ziegler, Rainer Stange, Karel Kostev","doi":"10.3390/antibiotics13100982","DOIUrl":null,"url":null,"abstract":"Background: The goal of this study was to evaluate whether the medical recommendation of Angocin®Anti-Infekt N (heretofore referenced as Angocin®) on the day of diagnosis of acute bronchitis is negatively associated with the recurrence of acute bronchitis diagnosis, antibiotic prescriptions, incidence of chronic bronchitis, and duration of sick leave.Methods: This study included patients in general practices in Germany with a first documented diagnosis of acute bronchitis between 2005 and 2022 (index date) and a prescription of Angocin®, thyme products, essential oils, mucolytics or antibiotics on the index date. The association between Angocin® prescription and the risks of a relapse of acute bronchitis, development of chronic bronchitis, or subsequent antibiotic prescription were evaluated using Cox regression models. Univariable conditional logistic regression models were used to investigate the association between Angocin® prescription and duration of sick leave.Results: After a 1:5 propensity score matching, 598 Angocin® patients and 2990 patients in each of the four comparison cohorts were available for analysis. Angocin® prescription was associated with significantly lower incidence of a renewed confirmed diagnosis of acute bronchitis as compared to essential oils (Hazard ratio (HR): 0.61; 95% Confidence Interval (CI): 0.46-0.80), thyme products (HR: 0.70; 95% CI: 0.53-0.91), mucolytics (HR: 0.65; 95% CI: 0.49-0.85) or antibiotics (HR: 0.64; 95% CI: 0.49-0.84). Also, there were significantly lower incidences of subsequent re-prescriptions of antibiotics when compared to mucolytics (HR: 0.73; 95% CI: 0.53-0.99) or antibiotics (HR: 0.53; 95% CI: 0.39-0.72) and a significantly lower risk of chronic bronchitis as compared to essential oils (HR: 0.60; 95% CI: 0.46-0.78), thyme products (HR: 0.53; 95% CI: 0.41-0.69), mucolytics (HR: 0.49; 95% CI: 0.38-0.63) or antibiotics (HR: 0.59; 95% CI: 0.45-0.76).Conclusions: Considering the limitations of the study, the results shed light on the sustaining effectiveness of Angocin® prescription in the management of acute bronchitis and the associated outcomes when compared to several other treatments commonly used for this condition.","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"13 10","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505283/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics13100982","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The goal of this study was to evaluate whether the medical recommendation of Angocin^®Anti-Infekt N (heretofore referenced as Angocin^®) on the day of diagnosis of acute bronchitis is negatively associated with the recurrence of acute bronchitis diagnosis, antibiotic prescriptions, incidence of chronic bronchitis, and duration of sick leave.

Methods: This study included patients in general practices in Germany with a first documented diagnosis of acute bronchitis between 2005 and 2022 (index date) and a prescription of Angocin^®, thyme products, essential oils, mucolytics or antibiotics on the index date. The association between Angocin^® prescription and the risks of a relapse of acute bronchitis, development of chronic bronchitis, or subsequent antibiotic prescription were evaluated using Cox regression models. Univariable conditional logistic regression models were used to investigate the association between Angocin^® prescription and duration of sick leave.

Results: After a 1:5 propensity score matching, 598 Angocin^® patients and 2990 patients in each of the four comparison cohorts were available for analysis. Angocin^® prescription was associated with significantly lower incidence of a renewed confirmed diagnosis of acute bronchitis as compared to essential oils (Hazard ratio (HR): 0.61; 95% Confidence Interval (CI): 0.46-0.80), thyme products (HR: 0.70; 95% CI: 0.53-0.91), mucolytics (HR: 0.65; 95% CI: 0.49-0.85) or antibiotics (HR: 0.64; 95% CI: 0.49-0.84). Also, there were significantly lower incidences of subsequent re-prescriptions of antibiotics when compared to mucolytics (HR: 0.73; 95% CI: 0.53-0.99) or antibiotics (HR: 0.53; 95% CI: 0.39-0.72) and a significantly lower risk of chronic bronchitis as compared to essential oils (HR: 0.60; 95% CI: 0.46-0.78), thyme products (HR: 0.53; 95% CI: 0.41-0.69), mucolytics (HR: 0.49; 95% CI: 0.38-0.63) or antibiotics (HR: 0.59; 95% CI: 0.45-0.76).

Conclusions: Considering the limitations of the study, the results shed light on the sustaining effectiveness of Angocin^® prescription in the management of acute bronchitis and the associated outcomes when compared to several other treatments commonly used for this condition.

查看原文本刊更多论文

调查草药复方制剂（Angocin®Anti-Infekt N）治疗急性支气管炎的效果：一项回顾性真实世界队列研究。

研究背景本研究的目的是评估急性支气管炎确诊当天推荐使用 Angocin®Anti-Infekt N（以下简称 Angocin®）是否与急性支气管炎复发、抗生素处方、慢性支气管炎发病率和病假时间呈负相关：研究对象包括 2005 年至 2022 年（指数日期）期间在德国全科诊所首次确诊急性支气管炎并在指数日期开具 Angocin®、百里香产品、精油、粘液溶解剂或抗生素处方的患者。采用 Cox 回归模型评估了 Angocin® 处方与急性支气管炎复发、慢性支气管炎发展或后续抗生素处方之间的关联。单变量条件逻辑回归模型用于研究 Angocin® 处方与病假持续时间之间的关系：经过 1:5 倾向评分匹配后，四个对比队列中各有 598 名 Angocin® 患者和 2990 名患者可供分析。与精油（危险比 (HR)：0.61；95% 置信区间 (CI)：0.46-0.80）、百里香产品（HR：0.70；95% 置信区间 (CI)：0.53-0.91）、粘液溶解剂（HR：0.65；95% 置信区间 (CI)：0.49-0.85）或抗生素（HR：0.64；95% 置信区间 (CI)：0.49-0.84）相比，Angocin®处方与再次确诊急性支气管炎的发生率明显较低。此外，与粘液溶解剂（HR：0.73；95% CI：0.53-0.99）或抗生素（HR：0.53；95% CI：0.39-0.72）相比，随后再次开具抗生素处方的发生率明显较低。72）和慢性支气管炎的风险明显低于精油（HR：0.60；95% CI：0.46-0.78）、百里香产品（HR：0.53；95% CI：0.41-0.69）、粘液溶解剂（HR：0.49；95% CI：0.38-0.63）或抗生素（HR：0.59；95% CI：0.45-0.76）：考虑到研究的局限性，研究结果阐明了安格列汀®处方在急性支气管炎治疗中的持续有效性，以及与其他几种常用治疗方法相比的相关结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antibiotics-Basel Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics

CiteScore

7.30

自引率

14.60%

发文量

1547

审稿时长

11 weeks

期刊介绍： Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.